In clinical exome and genome sequencing, there is a potential for the recognition and
reporting of incidental or secondary findings unrelated to the indication for ordering the …

Disclaimer: These recommendations are designed primarily as an educational resource for
medical geneticists and other healthcare providers to help them provide quality medical …

Purpose By incorporating major developments in genetics, ophthalmology, dermatology,
and neuroimaging, to revise the diagnostic criteria for neurofibromatosis type 1 (NF1) and to …

Neurofibromatosis type 1 is a complex autosomal dominant disorder caused by germline
mutations in the NF1 tumour suppressor gene. Nearly all individuals with neurofibromatosis …

Germline mutations in the tumour suppressor gene PTEN have been implicated in two
hamartoma syndromes that exhibit some clinical overlap, Cowden syndrome (CS) and Bannayan-…

Neurofibromatosis type 1 (NF1) is an autosomal dominant, multisystem disorder affecting
approximately 1 in 3500 people. Significant advances in the understanding of the …

Plexiform neurofibromas are among the most common and debilitating complications of
neurofibromatosis type 1 (NF1). They account for substantial morbidity, including disfigurement, …

Methods: The National Neurofibromatosis Foundation convened an expert task force to
review current knowledge about cardiovascular manifestations of NF1 and to make …

Neurofibromatosis type 1 (NF1) represents a major risk factor for development of malignancy,
particularly malignant peripheral nerve sheath tumors (MPNST), optic gliomas, other …

The chr12q24.13 locus encoding OAS1–OAS3 antiviral proteins has been associated with
coronavirus disease 2019 (COVID-19) susceptibility. Here, we report genetic, functional and …